L5 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:778751 CAPLUS
DN 137:296570
TI 3-Methoxybenzylthiourea derivatives as antioxidants for lipid compositions
IN Abbott, Thomas P.; Wohlman, Alan
PA The Fanning Corporation, USA
SO U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 840,768.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002147365	A1	20021010	US 2002-75418	20020214
	US 6586628	B2	20030701		
	US 2001056205	A1	20011227	US 2001-840768	20010423
	US 6653505	B2	20031125		
	EP 1479370	A1	20041124	EP 2004-19771	20010423
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	US 2003204113	A1	20031030	US 2003-426122	20030429
	US 2004030188	A1	20040212	US 2003-633252	20030801
PRAI	US 2000-202562P	P	20000510		
	US 2001-840768	A2	20010423		
	EP 2001-933368	A3	20010423		
	US 2002-75418	A1	20020214		

OS MARPAT 137:296570
AB Antioxidant 1-(3-methoxybenzyl)-3-substituted thioureas, 3-MeOC6H4CH2NHCSNHR (I, R = linear or branched alkyl, cycloalkyl, benzoyl, etc.) and improved lipid compns. which are supplemented with I in amts. effective for augmenting oxidative stability of the base lipid are provided. Methods are also provided for enhancing the oxidative stability of a lipid, comprising supplementing a base lipid in need of enhanced oxidative stability with 1-(3-methoxybenzyl)-3-substituted thiourea(s). Thus, oxidative stability of high-oleic sunflower oil was improved by more than 17-fold after addition of 1,3-di(3-methoxybenzyl)thiourea. The presence of a benzylamine or N-substituted benzylamine imparts enhanced oxidative stability.
IT **373642-48-9P 467434-73-7P**
RL: ADV (Adverse effect, including toxicity); NUU (Other use, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(methoxybenzylthiourea derivs. as antioxidants for lipid compns.)
RN 373642-48-9 CAPLUS
CN Thiourea, N-[(3-methoxyphenyl)methyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 467434-73-7 CAPLUS
CN Thiourea, N-[(3-methoxyphenyl)methyl]-N'-octadecyl- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:324835 CAPLUS
DN 138:57763
TI 1,3-Di(3-Methoxybenzyl) thiourea and related lipid antioxidants
AU Abbott, Thomas P.; Wohlman, Alan; Isbell, Terry; Momany, Frank A.; Cantrell, Charles; Garlotta, Donald V.; Weisleder, David
CS United States Department of Agriculture, Agricultural Research Service, National Center for Agricultural Utilization Research, Peoria, IL, 61604, USA
SO Industrial Crops and Products (2002), 16(1), 43-57
CODEN: ICRDEW; ISSN: 0926-6690
PB Elsevier Science B.V.
DT Journal
LA English
AB Natural lipids and oils are subject to oxidative degradation affecting color, odor, viscosity, and lubricity, which lowers the quality of the com. products containing these lipids. In the food, cosmetics and pharmaceutical industries, maintaining high quality color and odor of oils and other lipids is important. Meadowfoam (Limnanthes alba) seed oil is more oxidatively stable than other vegetable oils and imparts this oxidative stability to other oils when mixed in combinations. This study was conducted to identify antioxidants in meadowfoam oil and to determine their properties. Structurally-related compds. were synthesized to compare to the antioxidant compound in meadowfoam. Compds. isolated from meadowfoam oil (L. alba), were concluded to be either a source of 1,3-di(3-methoxybenzyl) thiourea (3MBTU) or oxidation products from it. 3-Methoxybenzyl isothiocyanate (3MBITC) and 3-methoxybenzyl amine (3MBAm), which were identified in the oil as degradation products of the glucosinolate glucolimnanthin, reacted readily to form 3MBTU in meadowfoam oil, water and ethanol. 1,3-di(3-methoxybenzyl) urea, the oxygenated form of 3MBTU, was isolated from crude meadowfoam oil. 3MBTU and other disubstituted thioureas containing at least one 3-methoxybenzyl substituent were made from isothiocyanates and amines and the lipid solubility, antioxidant properties, toxicity (LC50), stability and spectral absorbance properties were determined 3MBTU was an effective antioxidant in two different oxidative stability tests for mono- and polyunsatd. oils at the 0.1% level. It was also a stronger UVB absorber than most of the other disubstituted thioureas tested. Mol. models and calcns. explained some of these results. The toxicity of 3MBTU was also very low compared with other thioureas and some commonly used lipid antioxidants. Solubility in meadowfoam oil was highest for 3MBTU, among those tested at 50°. In conclusion, 3MBTU, from meadowfoam oil, meadowfoam byproducts, or synthesized appears to meet many of the criteria for an effective lipid antioxidant.
IT **373642-48-9 467434-73-7**
RL: MOA (Modifier or additive use); PRP (Properties); USES (Uses)
(thioureas and related lipid antioxidants for vegetable oil)
RN 373642-48-9 CAPLUS
CN Thiourea, N-[(3-methoxyphenyl)methyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 467434-73-7 CAPLUS
CN Thiourea, N-[(3-methoxyphenyl)methyl]-N'-octadecyl- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:833271 CAPLUS
DN 135:373244
TI 3-Methoxybenzyl thiourea derivatives and improved lipid compositions containing same
IN Abbott, Thomas P.; Wohlman, Alan
PA USA
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001085681	A2	20011115	WO 2001-US40587	20010423
	WO 2001085681	A3	20020606		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2406533	AA	20011115	CA 2001-2406533	20010423
	EP 1280495	A2	20030205	EP 2001-933368	20010423
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003532705	T2	20031105	JP 2001-582282	20010423
	EP 1479370	A1	20041124	EP 2004-19771	20010423
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	EP 1155677	A2	20011121	EP 2001-401057	20010425
	EP 1155677	A3	20020109		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 2000-202562P	P	20000510		
	EP 2001-933368	A3	20010423		
	WO 2001-US40587	W	20010423		

OS MARPAT 135:373244
AB 1-(3-Methoxybenzyl)-3-substituted thiourea antioxidant compds. and improved lipids compns. which are supplemented with amts. of such antioxidant compds. effective for augmenting oxidative stability of the base lipid are provided. Also provided are methods for enhancing the oxidative stability of a lipid comprising supplementing a base lipid in need of enhanced oxidative stability with at least one 1-(3-methoxybenzyl)-3-substituted thiourea compound of the present invention. Thus, 2.59 mL 3-methoxybenzyl isothiocyanate was added dropwise to 3.6 g 3-methoxybenzylamine in 20 mL water to give 1,3-di(3-methoxybenzyl)thiourea, 20 mg of which was added to jojoba oil showing 30% improvement on oxygen stability index compared to an OSI test for the jojoba oil alone.
IT **373642-48-9**
RL: MOA (Modifier or additive use); USES (Uses)
(stabilizer; 3-methoxybenzyl thiourea derivs. and improved lipid compns. containing same)

RN 373642-48-9 CAPLUS
CN Thiourea, N-[(3-methoxyphenyl)methyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:857578 CAPLUS
DN 141:350189
TI Preparation of novel quinazolines as MCH receptor antagonists
IN Sekiguchi, Yoshinori; Kanuma, Kosuke; Omodera, Katsunori; Busujima, Tsuyoshi; Tran, Thuy-Anh; Han, Sangdon; Casper, Martin; Kramer, Bryan A.
PA Taisho Pharmaceutical Co., Ltd., Japan; Arena Pharmaceuticals Inc.
SO PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004087680	A1	20041014	WO 2004-JP4554	20040330

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-458424P P 20030331
OS MARPAT 141:350189
GI



I



II

AB The title compds. QLYR1 [I; Q = (un)substituted 2-quinazolinyl; R1 = (un)substituted alkyl, cycloalkyl, aryl, etc.; L = II, III (wherein R5, R6 = H, alkyl; A, B = a bond, CH2, (CH2)2), etc.; Y = (un)substituted CONH, CSNH, C(O)O, SO2, etc.] which act as MCH receptor antagonists, were prepared E.g., a multi-step synthesis of 1-(3,4-dimethoxyphenyl)-3-[cis-4-(4-dimethylaminoquinazolin-2-ylamino)cyclohexyl]-urea hydrochloride (starting from quinazoline-2,4-dione) which showed IC50 of 13 nM against MCH receptor binding, was given. The compds. I are useful in pharmaceutical compns. (claimed) which use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

IT **774206-53-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel quinazolines as MCH receptor antagonists)

RN 774206-53-0 CAPLUS
CN Thiourea, N-[[cis-4-[[4-(dimethylamino)-2-quinazolinyl]amino]cyclohexyl]methyl]-N'-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:686361 CAPLUS
DN 140:174414
TI Synthesis of N-benzyl- and N-phenyl-2-amino-4,5-dihydrothiazoles and thioureas and evaluation as modulators of the isoforms of nitric oxide synthase
AU Goodyer, Claire L. M.; Chinje, Edwin C.; Jaffar, Mohammed; Stratford, Ian J.; Threadgill, Michael D.
CS Department of Pharmacy & Pharmacology, University of Bath, Bath, BA2 7AY, UK
SO Bioorganic & Medicinal Chemistry (2003), 11(19), 4189-4206
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Science Ltd.
DT Journal
LA English
AB Inhibition of the isoforms of nitric oxide synthase (NOS) has important applications in therapy of several diseases, including cancer. Using 1400W [N-(3-aminomethylbenzyl)acetamidine], thiocitrulline and Nδ-(4,5-dihydrothiazol-2-yl)ornithine as lead compds., series of N-benzyl- and N-phenyl-2-amino-4,5-dihydrothiazoles and thioureas were designed as inhibitors of NOS. Ring-substituted benzyl and Ph isothiocyanates were synthesized by condensation of the corresponding amines with thiophosgene and addition of ammonia gave the corresponding thioureas in high yields. The substituted 2-amino-4,5-dihydrothiazoles were approached by two routes. Treatment of simple benzylamines with 2-methylthio-4,5-dihydrothiazole at 180° afforded the corresponding 2-benzylamino-4,5-dihydrothiazoles. For less nucleophilic amines and those carrying more thermally labile substituents, the 4,5-dihydrothiazoles were approached by acid-catalyzed cyclization of N-(2-hydroxyethyl)thioureas. This cyclization was shown to proceed by an SN2-like process. Modest inhibitory activity was shown by most of the thioureas and 4,5-dihydrothiazoles, with N-(3-aminomethylphenyl)thiourea (IC50=13 μM vs. rat neuronal NOS and IC50=23 μM vs. rat inducible NOS) and 2-(3-aminomethylphenylamino)-4,5-dihydrothiazole (IC50=13 μM vs. rat neuronal NOS and IC50=19 μM vs. human inducible NOS) being the most potent. Several thioureas and 4,5-dihydrothiazoles were found to stimulate the activity of human inducible NOS in a time-dependent manner.
IT **366786-85-8P**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and NOS-inhibiting activity of N-benzyl- and N-Ph-2-amino-4,5-dihydrothiazoles and thioureas)
RN 366786-85-8 CAPLUS
CN Thiourea, N-(2-hydroxyethyl)-N'-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:540139 CAPLUS
DN 137:98670
TI Methods and compositions for inhibiting free radical polymerization in skin and hair
IN Wohlman, Alan; O'Lenick, Anthony J.
PA Fan Tech Ltd., UK
SO U.S. Pat. Appl. Publ., 7 pp., Cont.-in-part of U.S. Provisional Ser. No. 202,562.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002094342	A1	20020718	US 2000-725560	20001129
	US 6545052	B2	20030408		
	EP 1479370	A1	20041124	EP 2004-19771	20010423
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	EP 1155677	A2	20011121	EP 2001-401057	20010425
	EP 1155677	A3	20020109		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 2003114532	A1	20030619	US 2003-338313	20030108
PRAI	US 2000-202562P	P	20000510		
	US 2000-725560	A1	20001129		
	EP 2001-933368	A3	20010423		

OS MARPAT 137:98670
AB A method is provided for inhibiting free radical degradation in the skin of a human or nonhuman animal comprising contacting the skin with a skin treatment composition having a concentration of a 1-(3-methoxybenzyl)-3-substituted thiourea compound effective for inhibiting free radical generation. Skin protecting compns. comprising a free radical inhibiting concentration of a 1-(3-methoxybenzyl)-3-substituted thiourea compound, and optionally a sunscreen composition, are also provided. A skin treatment composition was prepared by blending 66 g mineral oil with 2.0 g 1,3-di-(3-methoxybenzyl) thiourea, 3.0 g 2-ethylhexyl palmitate, 27.0 g iso-Pr myristate and an effective amount of a suitable fragrance.
IT **373642-58-1P**
RL: COS (Cosmetic use); IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzylthiourea derivs. for inhibiting free radical polymerization in skin and hair)
RN 373642-58-1 CAPLUS
CN Thiourea, N,N'-bis[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



IT **373642-13-8 373642-15-0 373642-31-0**
442514-39-8
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzylthiourea derivs. for inhibiting free radical polymerization in skin and hair)
RN 373642-13-8 CAPLUS
CN Thiourea, N-ethyl-N'-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 373642-15-0 CAPLUS
CN Thiourea, N-[(3-methoxyphenyl)methyl]-N'-propyl- (9CI) (CA INDEX NAME)



RN 373642-31-0 CAPLUS
CN Thiourea, N-hexyl-N'-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 442514-39-8 CAPLUS
CN Thiourea, N-dodecyl-N'-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:369027 CAPLUS
DN 136:363872
TI Preparation of thiourea compounds for modulating α-adrenergic receptor activity and use in the treatment of pain
IN Chow, Ken; Gil, Daniel W.; Fang, Wenkui; Garst, Michael E.; Wheeler, Larry A.
PA Allergan Sales, Inc., USA
SO U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 548,315, abandoned.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002058839	A1	20020516	US 2001-778975	20010205
	US 6545182	B2	20030408		
PRAI	US 2000-548315	B2	20000413		

OS MARPAT 136:363872
GI



I

AB Methods and compns. are disclosed which use thiourea compds. I (R1, R5 = halo, alkyl, alkoxy, etc.; R2, R4 = halo, alkyl, alkoxy, etc.; R3 = F, H), and alkyl esters thereof, for the treatment of pain. Preparation of I [R1 = F; R2 = Cl; R3-R5 = H] which showed EC50 of 16 nM and 457 nM at α2B and α2C receptor in RSAT assay, was given. Particularly disclosed are compns. for the treatment of chronic pain, and methods for their use.

IT **366786-85-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiourea compds. for modulating α-adrenergic receptor activity and use in treatment of pain)

RN 366786-85-8 CAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:43035 CAPLUS

DN 136:102404

TI Synthesis of disubstituted piperazinyl derivatives as CCR-3 receptor antagonists

IN Gong, Leyi; Kertesz, Denis John; Smith, David Bernard; Talamas, Francisco Xavier; Wilhelm, Robert Stephen

PA Syntex (U.S.A.) LLC, USA

SO U.S., 41 pp., Cont.-in-part of U.S. Ser. No. 134,013.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6339087	B1	20020115	US 1998-197282	19981120
	US 6323223	B1	20011127	US 1998-134013	19980814
	US 2003153577	A1	20030814	US 2001-942204	20010829
	US 6770650	B2	20040803		
	US 6683074	B1	20040127	US 2001-965068	20010926
	US 2004266782	A1	20041230	US 2003-719204	20031121
PRAI	US 1997-56001P	P	19970818		
	US 1998-134013	A2	19980814		
	US 1998-197282	A3	19981120		
	US 2001-965068	A3	20010926		

OS MARPAT 136:102404

GI



I



II

AB Title compds. I [R1-2 = H, alkyl; m = 0-3; F = alkylene, alkenylene, bond; R = H, alkyl or R together with R4 and the atoms to which they are attached form a carbocycle; R3 = H; R4 = alkyl, haloalkyl, cycloalkyl, alkyl-SO0-2, alkylene-C(O)-Z, where Z = alkoxy, hydroxyalkyl; E = ureido, thioureido, amido, carboxamido,Ar = substituted aryl optionally substituted with one, two or three alk(en)yl, alkoxy, haloalkoxy, halo, aryl, heteroaryl, etc.; Ar1 = (un)substituted aryl, optionally substituted with one, two or three alkyl, heteroalkyl, alkoxy, halo, haloalkyl, haloalkoxy, alkylthio, methylenedioxy, nitro, amino or a combination thereof; Q = alkylene-W, where W = bond, O, S, O2C, carboxamido or C(O)] were prepared For example, N-Boc-piperazine was alkylated with 3,4-dichlorobenzyl bromide (CHCl3, Et3N, 1 h), deprotected (CHCl3, TFA, 1 h) and coupled to Boc-L-valine (CH2Cl2, EDCI, 2 h) to give the N-protected piperazinylamide intermediate. Deprotection (MeOH, HCl, 70°C, 2.5 h) followed by amide reduction (THF, BH3, reflux, 2 h) and acylation with p-toluoyl chloride (CH2Cl2, Et3N, 1 h) yielded II which was isolated as the dihydrochloride salt. The IC50 value (concentration of test compound required to reduce 125I-eotaxin binding to the CCR-3 L 1.2 transfected cells by 50%) for selected compds. I was 0.24 - 3.52 μM. Compds. I are useful in treating inflammatory or allergic diseases, e.g., asthma, allergic rhinitis, etc.

IT **220772-46-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; synthesis of disubstituted piperazinyl derivs. as CCR-3 receptor antagonists)

RN 220772-46-3 CAPLUS
CN Thiourea, N-[1-[[4-[(3,4-dichlorophenyl)methyl]-1-piperazinyl]methyl]-2-methylpropyl]-N'-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:780661 CAPLUS
DN 135:298811
TI Thiourea compounds for modulating α-adrenergic receptor activity, preparation, compositions, and use in the treatment of pain

IN Chow, Ken; Gil, Daniel W.; Fang, Wenkui Ken; Garst, Michael E.; Wheeler, Larry A.
PA Allergan Sales, Inc., USA
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001078702	A2	20011025	WO 2001-US11842	20010411
	WO 2001078702	A3	20020321		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2405796	AA	20011025	CA 2001-2405796	20010411
	EP 1280524	A2	20030205	EP 2001-926875	20010411
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003530429	T2	20031014	JP 2001-576003	20010411
PRAI	US 2000-548315	A	20000413		
	WO 2001-US11842	W	20010411		

OS MARPAT 135:298811
GI



I

AB Methods and compns. are disclosed which use thiourea compds. I (R1, R2, R4, R5 = H, OH, C1-3 alkyl, etc.; R3 = H, F), and alkyl esters thereof, for the treatment of pain. Particularly disclosed are compns. for the treatment of chronic pain, and methods for their use.

IT **366786-85-8**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thiourea compds. for modulating α-adrenergic receptor activity, preparation, compns., and use in treatment of pain)

RN 366786-85-8 CAPLUS
CN Thiourea, N-(2-hydroxyethyl)-N'-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:147946 CAPLUS
DN 130:196670
TI Arylcarbamoylalkylpiperazines and -piperidines as CCR-3-receptor antagonists
IN Gong, Leyi; Kertesz, Denis John; Smith, David Bernard; Talamas, Francisco Xavier; Wilhelm, Robert Stephen
PA F. Hoffmann-La Roche A.-G., Switz.
SO Ger. Offen., 60 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19837386	A1	19990225	DE 1998-19837386	19980818
	EP 903349	A2	19990324	EP 1998-114971	19980810
	EP 903349	A3	20000524		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	NZ 331319	A	20000327	NZ 1998-331319	19980811
	CA 2245043	AA	19990218	CA 1998-2245043	19980814
	ES 2154167	A1	20010316	ES 1998-1760	19980814
	ES 2154167	B1	20011101		
	NO 9803749	A	19990219	NO 1998-3749	19980817
	GB 2330580	A1	19990428	GB 1998-17910	19980817
	AU 9880800	A1	19990225	AU 1998-80800	19980818
	AU 744059	B2	20020214		
	FR 2767826	A1	19990305	FR 1998-10504	19980818
	CN 1211572	A	19990324	CN 1998-117990	19980818
	CN 1107061	B	20030430		
	JP 11147872	A2	19990602	JP 1998-231918	19980818
	JP 3014367	B2	20000228		
	SG 70110	A1	20000125	SG 1998-3133	19980818
	BR 9803179	A	20000328	BR 1998-3179	19980818
	IT 1304150	B1	20010308	IT 1998-MI1902	19980818
PRAI	US 1997-56001P	P	19970818		

OS MARPAT 130:196670
GI



I

AB Title compds. I [Ar, Ar1 = aryl, heteroaryl; E = (un)substituted CONH, SO2NH, NHCONH, NHSO2NH, NHCSNH, NHCO, NHCO2, O2CNH, NHSO2; F = alkylene, alkenylene; R = H, alkyl; R1, R2 = H, alkyl; R3, R4 = H, (un)substituted alkyl, cycloalkyl, heterocyclic, CN; CR3R4 = carbocyclic, heterocyclic; RR3 = atoms required to form a carbocyclic or heterocyclic ring; Q = (un)substituted alkylene, heteroalkylene; one of T an U = N, the other is N or CH; n = 0-2] were prepared for use as CCR-3 receptor antagonists, useful in treating asthma in particular. Thus, N-[(1S)-[4-(3,4-dichlorobenzyl)piperazin-1-ylmethyl]-2-methylpropyl]-4-methylbenzamide.2HCl was prepared from 1-(3,4-dichlorobenzyl)piperazine and BOC-L-valine in 4 steps. This compound had an IC50 for CCR-3 receptor binding of 0.24 μM.

IT **220772-46-3P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylcarbamoylalkylpiperazines and -piperidines as CCR-3-receptor antagonists)

RN 220772-46-3 CAPLUS

CN Thiourea, N-[1-[[4-[(3,4-dichlorophenyl)methyl]-1-piperazinyl]methyl]-2-methylpropyl]-N'-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



(FILE 'HOME' ENTERED AT 17:16:31 ON 12 MAY 2005)

FILE 'REGISTRY' ENTERED AT 17:16:39 ON 12 MAY 2005
L1 STRUCTURE UPLOADED
L2 2 S L1
L3 29 S L1 FUL

FILE 'CAPLUS, CA' ENTERED AT 17:17:55 ON 12 MAY 2005

FILE 'CAPLUS, CAOLD' ENTERED AT 17:18:15 ON 12 MAY 2005
L4 3 S L2
L5 3 DUP REM L4 (0 DUPLICATES REMOVED)
L6 10 S L3
L7 7 S L6 NOT L5
L8 7 DUP REM L7 (0 DUPLICATES REMOVED)

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.